Shuttle Pharmaceuticals Holdings, Inc.SHPH
Price (close)
$4.00
Market cap
$19.1M
P/E
—
Revenue (TTM)
—
Net income
-$10.3M
Dividend yield
—
1-year total return
-90.3%
Net margin
—
Revenue growth
—
Debt / equity
—
What Shuttle Pharmaceuticals Holdings, Inc. does.
November 21, 2025, we acquired substantially all of the assets and liabilities of Molecule.ai, a pharmaceutical software company
building an artificial intelligence (“AI”) driven platform for molecular discovery and early-stage drug development. By combining modern AI techniques with structured scientific workflows, the Molecule.ai
evaluate molecular ideas with greater clarity and make more informed decisions during the earliest stages of drug development. The platform
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | — | -$1.2M | -$5.0M | -$6.6M | -$9.1M | -$11.7M |
| Free cash flow | — | — | — | -$5.6M | — | — |
More on SHPH.
- Shuttle Pharmaceuticals Holdings, Inc. summary
- Shuttle Pharmaceuticals Holdings, Inc. financial statements
- Shuttle Pharmaceuticals Holdings, Inc. key metrics
- Shuttle Pharmaceuticals Holdings, Inc. health scores and style box
- Shuttle Pharmaceuticals Holdings, Inc. earnings
- Shuttle Pharmaceuticals Holdings, Inc. dividends
- Shuttle Pharmaceuticals Holdings, Inc. valuation
- Shuttle Pharmaceuticals Holdings, Inc. ownership and insiders
- Shuttle Pharmaceuticals Holdings, Inc. peers
Figures from Shuttle Pharmaceuticals Holdings, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.